Table 7.

Patents that played a role in the dispute between BMS and Repligen regarding abatacept

Patent No	Title	Priority date	Inventors	claimed subject matter	Assignee
US5851795	Soluble CTLA4 molecules and uses thereof	June 27, 1991	LINSLEY et al	soluble CTLA4 molecule having the extracellular domain of CTLA4 which binds B7 expressed on activated B cells	BMS
US5885579	CTLA4 receptor and uses thereof			method for regulating functional CTLA4 positive T cell interactions with B7 positive cells or treating immune system diseases by administering a ligand for B7 antigen, which ligand is preferably CTLA4-E7, CTLA4-p97 or CTLA4-env gp120.
US5885796	CTLA4 receptor and uses thereof			CTLA4 receptor protein having the amino acid sequence (SEQ ID NO: 14
US5968510	CTLA4 receptor and uses thereof			method for regulating CTLA4 positive T cell interactions with B7 positive B cells by contact the T cells with a monoclonal antibody, Fab or F(ab')2 fragment reactive with CTLA4
US5977318	CTLA4 receptor and uses thereof			antibody which binds extracellular domain of CTLA4 and prevents binding of CTLA4 to B7
US5844095	CTLA4 Ig fusion proteins			CTLA4Ig fusion protein which binds B7, consisting of CTLA4 extracellular domain plus hinge, CH2 and CH3 regions of a human IgG
US5434131	Ctl4a receptor, fusion proteins containing it and uses thereof			method for regulating CTLA4 positive T cell interactions with B7 positive cells comprising contacting said B7 positive cells with a fusion protein that contains a portion of the extracellular domain of CTLA4
US6685941	Methods of treating autoimmune disease via CTLA-4Ig	Nov 23, 1988	THOMPSON + JUNE	method of treating multiple sclerosis or systemic lupus erythematosis by administration of CTLA-4Ig to suppress the patient's immune response	UNIV MICHIGAN